食管癌组织中ErbB3、miR-27a表达情况及与临床预后的关系

doi:10.3760/cma.j.issn.1007-1245.2024.20.017

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (20): 3433-3437.DOI: 10.3760/cma.j.issn.1007-1245.2024.20.017

食管癌组织中ErbB3、miR-27a表达情况及与临床预后的关系

郭晓宁¹ 朱文龙² 宫惠琳³ 刘战飞²

¹杨凌示范区医院病理科，咸阳　712100；²杨凌示范区医院胸外肿瘤科，咸阳　712100；³西安交通大学第一附属医院病理科，西安　710061

收稿日期:2024-03-28 出版日期:2024-10-01 发布日期:2024-10-18
通讯作者: 刘战飞，Email：332448292@qq.com
基金资助:
陕西省重点研发计划（2021KW-47）

Expressions of ErbB3 and miR-27a in esophageal cancer tissues and their relationships with clinical prognosis

Guo Xiaoning¹, Zhu Wenlong², Gong Huilin³, Liu Zhanfei²

¹Department of Pathology, Yangling Demonstration Zone Hospital, Xianyang 712100, China; ²Extrathoracic Oncology Department, Yangling Demonstration Zone Hospital, Xianyang 712100, China; ³Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Received:2024-03-28 Online:2024-10-01 Published:2024-10-18
Contact: Liu Zhanfei, Email: 332448292@qq.com
Supported by:
Shaanxi Province Key Research and Development Plan (2021KW-47)

摘要/Abstract

摘要：

目的　探究食管癌组织中Erb-B2受体酪氨酸激酶3（ErbB3）、微RNA-27a（miR-27a）表达情况及与临床预后的关系。方法　回顾性选取2019年6月至2023年6月杨凌示范区医院病理科收治的120例食管癌患者作为研究对象。根据格拉斯哥预后评分（GPS）将患者分为预后良好组（97例）和预后不良组（23例）。选取50例同期体检的健康人员作为对照组。比较预后良好组和预后不良组一般资料，食管癌患者和对照组ErbB3、miR-27a表达水平。采用logistic回归分析食管癌患者预后的影响因素并构建列线图。采用Spearman相关性分析ErbB3、miR-27a与预后的相关性。采用受试者操作特征曲线（ROC）分析ErbB3、miR-27a对食管癌患者预后的预测效能。采用独立样本t检验、单因素方差分析和χ²检验。结果　预后良好组男55例，女42例；年龄47～68岁。预后不良组男14例，女9例；年龄45～66岁。预后不良组肿瘤分期Ⅲ期、淋巴结转移人数占比均高于预后良好组，低分化程度人数占比低于预后良好组（均P<0.05）。预后不良组ErbB3［（1.59±0.45）］、miR-27a［（2.59±0.95）］表达水平均高于预后良好组［（1.28±0.37）、（1.84±0.52）］和对照组［（0.72±0.28）（0.85±0.33）］，且预后良好组均高于对照组（均P<0.05）。logistic回归分析显示，肿瘤分期、分化程度、淋巴结转移、ErbB3和miR-27a表达水平均是食管癌患者预后的影响因素（均P<0.05）。Spearman相关性分析显示，食管癌患者ErbB3、miR-27a表达水平均与GPS呈正相关（r=0.294、0.282，P=0.001、0.002）。ROC分析结果表明，ErbB3、miR-27a联合预测的曲线下面积（AUC）大于ErbB3、miR-27a单独预测（0.873比0.715、0.715）。结论　食管癌组织中ErbB3、miR-27a表达水平对食管癌患者预后有良好评估价值。

关键词:

Erb-B2受体酪氨酸激酶3, 微RNA-27a, 食管癌, 预后

Abstract:

Objective　To investigate the expressions of Erb-B2 receptor tyrosine kinase 3 (ErbB3) and microRNA-27A (miR-27a) in esophageal cancer tissues and their relationships with clinical prognosis. Methods　A total of 120 patients with esophageal cancer admitted to the Department of Pathology, Yangling Demonstration Zone Hospital from June 2019 to June 2023 were retrospectively selected as the study objects. According to the Glasgow Prognostic Score (GPS), the patients were divided into a good prognosis group (97 cases) and a poor prognosis group (23 cases). Additionally, 50 healthy individuals undergoing routine health checks during the same period were selected as controls. The general data were compared between the good prognosis group and the poor prognosis group, and the expressions of ErbB3 and miR-27a were compared between the patients with esophageal cancer and the control group. Logistic regression analysis was used to analyze the factors influencing prognosis in patients with esophageal cancer, and a nomogram was constructed. Spearman correlation analysis was used to analyze the correlations between ErbB3 and miR-27a and prognosis. The predictive efficacies of ErbB3 and miR-27a for prognosis in patients with esophageal cancer were analyzed by the receiver operating characteristic curve (ROC). Independent sample t test, ANOVA, and χ² test were used. Results　There were 55 males and 42 females in the good prognosis group, aged 47-68 years. There were 14 males and 9 females in the poor prognosis group, aged 45-66 years. The proportions of the patients with stage III tumors and lymph node metastasis in the poor prognosis group were higher than those in the good prognosis group, and the proportion of the patients with low differentiation was lower than that in the good prognosis group (all P<0.05). The expression levels of ErbB3 [(1.59±0.45)] and miR-27a [(2.59±0.95)] in the poor prognosis group were higher than those in the good prognosis group [(1.28±0.37) and (1.84±0.52)] and the control group [(0.72±0.28) and (0.85±0.33)], and those in the good prognosis group were higher than those in the control group (all P<0.05). Logistic regression analysis showed that tumor stage, degree of differentiation, lymph node metastasis, and expressions of ErbB3 and miR-27a were all prognostic factors in patients with esophageal cancer (all P<0.05). Spearman correlation analysis showed that the expressions of ErbB3 and miR-27a in patients with esophageal cancer were positively correlated with GPS (r=0.294 and 0.282, P=0.001 and 0.002). ROC analysis results showed that the area under the curve (AUC) predicted by ErbB3 combined with miR-27a was greater than that predicted by ErbB3 or miR-27a alone (0.873 vs. 0.715 and 0.715). Conclusion　The expressions of ErbB3 and miR-27a in esophageal cancer tissues have significant prognostic value for patients with esophageal cancer.

Key words:

Erb-B2 receptor tyrosine kinase 3, microRNA-27A, Esophageal cancer, Prognosis

郭晓宁朱文龙宫惠琳刘战飞.

食管癌组织中ErbB3、miR-27a表达情况及与临床预后的关系 [J]. 国际医药卫生导报, 2024, 30(20): 3433-3437.

Guo Xiaoning, Zhu Wenlong, Gong Huilin, Liu Zhanfei.

Expressions of ErbB3 and miR-27a in esophageal cancer tissues and their relationships with clinical prognosis [J]. International Medicine and Health Guidance News, 2024, 30(20): 3433-3437.

参考文献

[1] Boudabbous M, Barkia B, Feki W, et al. Squamous cell carcinoma and Crohn's disease: a sometimes-challenging diagnosis[J]. Future Sci OA, 2024, 10(1):FSO907. DOI: 10.2144/fsoa-2023-0109.
[2] 宋春涛,于永洋,高振,等.局部晚期食管癌免疫治疗的现状及前景[J].实用肿瘤杂志,2023,38(2):195-201.DOI:10.13267/j.cnki.syzlzz.2023.031.
[3] 韦光楠,廖宁,陈博.HER2阳性乳腺癌ERBB3基因E928G点突变功能的初步研究[J].医学综述,2022,28(7):1441-1445.DOI:10.3969/j.issn.1006-2084.2022.07.034.
[4] 彭依琳,陈文欣,胡华,等.miR-27a低表达对子宫内膜癌HEC-1-A细胞增殖的影响[J].中南医学科学杂志,2023,51(3):360-362.DOI:10.15972/j.cnki.43-1509/r.2023.03.010.
[5] 杨剑洋,贺德,李志坚,等.miR-27a促进胃癌细胞AGS增殖与侵袭及其机制探讨[J].现代肿瘤医学,2022,30(12):2129-2135.DOI:10.3969/j.issn.1672-4992.2022.12.005.
[6] 赵蓓蓓,吴帅.miR-27a,miR-138-5p对食管癌的早期诊断价值及与其病理分化程度的关系研究[J].实用癌症杂志,2023,38(5):722-725,729.DOI:10.3969/j.issn.1001-5930. 2023.05.006.
[7] 刘诗宇,任建伟,刘洁莹.不同时间点中性粒细胞/淋巴细胞比值与急性脑出血后脑水肿程度和短期预后的关系[J].中国现代医学杂志,2021,31(9):18-22.DOI:10.3969/j.issn.1005-8982.2021.09.004.
[8] 赵灿,王刚,刘霄燕,等.格拉斯哥预后评分对心力衰竭患者预后的预测价值[J].中国循环杂志,2023,38(10):1024-1029.DOI:10.3969/j.issn.1000-3614.2023.10.004.
[9] 梁宗英,赵宝山,郑竞雄,等.乙酰基转移酶KAT2A和Survivin蛋白乙酰化在食管癌中的相关性研究[J].临床肿瘤学杂志,2023,28(1):16-22.DOI:10.3969/j.issn.1009- 0460.2023.01.003.
[10] 周阳,王聪,付民,等.miR-27a、miR-138-5p对食管癌患者术后生存情况的预测作用及与复发转移的关系[J].实用医学杂志,2021,37(22):2923-2927.DOI:10.3969/j.issn.1006-5725.2021.22.019.
[11] Lee HE, Malone J, Abdul-Baki K, et al. Metastatic signet ring cell adenocarcinoma manifesting as chronic leg pain[J]. ACG Case Rep J, 2023, 10(10):e01180. DOI: 10.14309/crj.0000000000001180.
[12] 王培伟,翁一鸣,崔雪,等.外周血生物标志物与免疫检查点抑制剂治疗晚期食管癌疗效的相关性[J].肿瘤防治研究,2023,50(1):58-62.DOI:10.3971/j.issn.1000-8578.2023. 22.0695.
[13] Yang QZ, Hu M, Li X, et al. Gastric carcinoma with lymphoid stroma and goblet cell adenocarcinoma: report of a case[J]. Zhonghua Bing Li Xue Za Zhi, 2023, 52(9):964-966. DOI: 10.3760/cma.j.cn112151-20230221- 00146.
[14] 杨雄涛.食管癌综合治疗新进展[J].中国肿瘤临床,2023,50(2):98-103.DOI:10.12354/j.issn.1000-8179.2023. 20221079.
[15] 苏晓雨,王青青,刘风侠.食管癌放疗病人症状群的纵向研究[J].护理研究,2023,37(1):12-20.DOI:10.12102/j.issn.1009-6493.2023.01.003.
[16] 路大鹏,赵卫林,王玉强,等.食管癌生存随访调查及列线图预后预测模型的建立[J].癌变.畸变.突变,2023,35(1):37-42.DOI:10.3969/j.issn.1004-616x.2023.01.007.
[17] 胡俊泽,谢权,马建伟,等.食管癌患者血清NLR LMR NMR与预后的关系研究[J].河北医学,2023,29(2):254-259.DOI:10.3969/j.issn.1006-6233.2023.02.014.
[18] 杨金华,赵天增,张岭.食管癌根治术患者血清microRNA-27a、microRNA-203a-3p表达及与预后的关系[J].中国现代医学杂志,2023,33(2):78-83.DOI:10.3969/j.issn.1005-8982.2023.02.013.
[19] Almangush A, Mäkitie AA, Triantafyllou A, et al. Staging and grading of oral squamous cell carcinoma: an update[J]. Oral Oncol, 2020, 107:104799. DOI: 10.1016/j.oraloncology.2020.104799.
[20] 汪圣毅,周浩,刘虎.胃癌外周血淋巴细胞数关联因素的横断面研究[J].安徽医科大学学报,2023,58(1):151-155.DOI:10.19405/j.cnki.issn1000-1492.2023.01.025.
[21] Mehta N, Dodge JL, Grab JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2020, 71(3):943-954. DOI: 10.1002/hep.30879.
[22] Kiran S, Xue Y, Sarker DB, et al. Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells[J]. Bioact Mater, 2024, 36:301-316. DOI: 10.1016/j.bioactmat.2024.02.031.
[23] Qin S, Jiang J, Lu Y, et al. Emerging role of tumor cell plasticity in modifying therapeutic response[J]. Signal Transduct Target Ther, 2020, 5(1):228. DOI: 10.1038/s41392-020-00313-5.
[24] 董峰,吴会芳,牛跃平,等.程序性死亡因子配体1与微卫星状态在低分化结直肠癌组织中的表达及临床意义[J].胃肠病学和肝病学杂志,2023,32(3):259-263.DOI:10.3969/j.issn.1006-5709.2023.03.005.
[25] 林杰,区活辉,王卫东,等.过表达CLEC5A基因抑制肝细胞癌增殖和转移并逆转上皮-间质转化[J].南方医科大学学报,2023,43(1):85-91.DOI:10.12122/j.issn.1673-4254.2023. 01.11.
[26] 于艳霞,许莎莎,晁芳芳,等.18F-FDG PET/CT检测淋巴结转移癌原发灶[J].中国医学影像技术,2023,39(9):1393-1396.DOI:10.13929/j.issn.1003-3289.2023.09.025.
[27] 徐业成,傅德良.胰腺癌淋巴结转移研究进展[J].肝胆外科杂志,2022,30(1):76-80.DOI:10.3969/j.issn.1006-4761. 2022.01.022.
[28] 孟午生,程娜,马晓红,等.FN1、LZTS2、ERBB3在甲状腺癌演进过程中表达水平变化分析[J].国际检验医学杂志,2022,43(20):2465-2469.DOI:10.3969/j.issn.1673-4130. 2022.20.006.
[29] 程龙,徐五琴,张鹏,等.下调miR-27a表达对三阴乳腺癌细胞增殖、迁移和侵袭的影响[J].上海交通大学学报(医学版),2020,40(2):188-193.DOI:10.3969/j.issn.1674-8115. 2020.02.007.
[30] 付民,尹先哲,尹星,等.miR-27a在食管癌细胞中的表达及其对食管癌细胞增殖和EMT特性的影响[J].热带医学杂志,2022,22(6):785-789.DOI:10.3969/j.issn.1672-3619. 2022.06.009.

食管癌组织中ErbB3、miR-27a表达情况及与临床预后的关系

Expressions of ErbB3 and miR-27a in esophageal cancer tissues and their relationships with clinical prognosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	余思燕高玲许鹏黄瑜芳. 食管癌患者围手术期规范化营养治疗现状 [J]. 国际医药卫生导报, 2024, 30(9): 1434-1439.
[2]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.
[3]	郭江红王欢吴妍. LTBP-2联合心肺联合超声预测老年急性心肌梗死患者短期预后的价值 [J]. 国际医药卫生导报, 2024, 30(8): 1233-1238.
[4]	杨星王秋茹周雪. 脂蛋白a和载脂蛋白B联合维生素D检测对冠心病严重程度及短期预后的评估价值 [J]. 国际医药卫生导报, 2024, 30(8): 1238-1242.
[5]	吴鹏杨鸿炜李朝杰. 经肛门内镜下黏膜剥离术治疗早期直肠癌患者的效果观察 [J]. 国际医药卫生导报, 2024, 30(7): 1181-1185.
[6]	吴媛媛刘科齐艳丽童小华. 非小细胞肺癌组织中CLCA4的表达情况及与病理和预后的关系 [J]. 国际医药卫生导报, 2024, 30(6): 903-907.
[7]	张国坤张天佑张景畅李素新. 原发性肝癌患者TACE预后不良的因素分析：基于PSM法 [J]. 国际医药卫生导报, 2024, 30(5): 747-753.
[8]	吕莹郝明硕钱阳王蕊相龙全. PTBP3对食管鳞状细胞癌细胞增殖与迁移的影响及机制研究 [J]. 国际医药卫生导报, 2024, 30(5): 797-802.
[9]	王海峰吴照锋侯中玉李亮. 葡萄球菌相关PS患者临床特征及预后分析 [J]. 国际医药卫生导报, 2024, 30(5): 834-838.
[10]	闫荣胡广翠逄红风于杰. 平板运动试验与静息心电图联合评估对冠心病的诊断价值 [J]. 国际医药卫生导报, 2024, 30(4): 619-622.
[11]	刘茗刘帅张楠. 早期乳腺癌患者保乳术后免除放疗的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 357-362.
[12]	时娟娟杜超李南韩珊珊崔秀娟. 难治性子宫腺肉瘤1例 [J]. 国际医药卫生导报, 2024, 30(3): 503-507.
[13]	崔玉霞杜冰高风双. 慢性疾病轨迹框架下自我护理模式对老年胃癌切除术患者的效果影响 [J]. 国际医药卫生导报, 2024, 30(3): 524-528.
[14]	白新朝贺维. 痉挛型脑瘫患儿康复治疗预后不良的因素探讨及风险预测方案研究 [J]. 国际医药卫生导报, 2024, 30(20): 3407-3412.
[15]	王凤韩钢. 类风湿关节炎患者血清指标与疾病活动度和骨密度的相关性 [J]. 国际医药卫生导报, 2024, 30(20): 3418-3422.